A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Clinical trial NCT03238027 · COMPLETED

Trial details

NCT number: NCT03238027
Sponsor: Syndax Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor Metastatic Tumor Locally Advanced Malignant Neoplasm Unresectable Malignant Neoplasm

Start date: 2017-09-01
Primary completion: 2020-11-20
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.